Frontiers in Medicine (Nov 2022)
Progression to lung fibrosis in severe COVID-19 patients: A morphological and transcriptomic study in postmortem samples
- Belén Pérez-Mies,
- Belén Pérez-Mies,
- Belén Pérez-Mies,
- Belén Pérez-Mies,
- Tamara Caniego-Casas,
- Tamara Caniego-Casas,
- Tamara Caniego-Casas,
- Tommaso Bardi,
- Tommaso Bardi,
- Irene Carretero-Barrio,
- Irene Carretero-Barrio,
- Irene Carretero-Barrio,
- Amparo Benito,
- Amparo Benito,
- Amparo Benito,
- Mónica García-Cosío,
- Mónica García-Cosío,
- Mónica García-Cosío,
- Irene González-García,
- Irene González-García,
- David Pizarro,
- David Pizarro,
- David Pizarro,
- Marta Rosas,
- Marta Rosas,
- Eva Cristóbal,
- Eva Cristóbal,
- Yolanda Ruano,
- María Concepción Garrido,
- Juan Rigual-Bobillo,
- Juan Rigual-Bobillo,
- Raúl de Pablo,
- Raúl de Pablo,
- Raúl de Pablo,
- Juan Carlos Galán,
- Juan Carlos Galán,
- Juan Carlos Galán,
- David Pestaña,
- David Pestaña,
- David Pestaña,
- José Palacios,
- José Palacios,
- José Palacios,
- José Palacios
Affiliations
- Belén Pérez-Mies
- Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain
- Belén Pérez-Mies
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- Belén Pérez-Mies
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- Belén Pérez-Mies
- Faculty of Medicine, Alcalá University, Alcalá de Henares, Spain
- Tamara Caniego-Casas
- Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain
- Tamara Caniego-Casas
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- Tamara Caniego-Casas
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- Tommaso Bardi
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- Tommaso Bardi
- Department of Anesthesiology and Surgical Critical Care, Hospital Ramón y Cajal, Madrid, Spain
- Irene Carretero-Barrio
- Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain
- Irene Carretero-Barrio
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- Irene Carretero-Barrio
- Faculty of Medicine, Alcalá University, Alcalá de Henares, Spain
- Amparo Benito
- Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain
- Amparo Benito
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- Amparo Benito
- Faculty of Medicine, Alcalá University, Alcalá de Henares, Spain
- Mónica García-Cosío
- Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain
- Mónica García-Cosío
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- Mónica García-Cosío
- Faculty of Medicine, Alcalá University, Alcalá de Henares, Spain
- Irene González-García
- Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain
- Irene González-García
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- David Pizarro
- Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain
- David Pizarro
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- David Pizarro
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- Marta Rosas
- Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain
- Marta Rosas
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- Eva Cristóbal
- Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain
- Eva Cristóbal
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- Yolanda Ruano
- Department of Pathology, Medical School, Universidad Complutense, Instituto i + 12, Hospital Universitario 12 de Octubre, Madrid, Spain
- María Concepción Garrido
- Department of Pathology, Medical School, Universidad Complutense, Instituto i + 12, Hospital Universitario 12 de Octubre, Madrid, Spain
- Juan Rigual-Bobillo
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- Juan Rigual-Bobillo
- Department of Respiratory, Hospital Universitario Ramón y Cajal, Madrid, Spain
- Raúl de Pablo
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- Raúl de Pablo
- Faculty of Medicine, Alcalá University, Alcalá de Henares, Spain
- Raúl de Pablo
- Medical Intensive Care Unit, Hospital Ramón y Cajal, Madrid, Spain
- Juan Carlos Galán
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- Juan Carlos Galán
- Clinical Microbiology Unit, Hospital Ramón y Cajal, Madrid, Spain
- Juan Carlos Galán
- 0Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- David Pestaña
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- David Pestaña
- Faculty of Medicine, Alcalá University, Alcalá de Henares, Spain
- David Pestaña
- Department of Anesthesiology and Surgical Critical Care, Hospital Ramón y Cajal, Madrid, Spain
- José Palacios
- Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain
- José Palacios
- Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain
- José Palacios
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- José Palacios
- Faculty of Medicine, Alcalá University, Alcalá de Henares, Spain
- DOI
- https://doi.org/10.3389/fmed.2022.976759
- Journal volume & issue
-
Vol. 9
Abstract
The development of lung fibrosis is a major concern in patients recovered from severe COVID-19 pneumonia. This study aimed to document the evolution of diffuse alveolar damage (DAD) to the fibrosing pattern and define the transcriptional programs involved. Morphological, immunohistochemical and transcriptional analysis were performed in lung samples obtained from autopsy of 33 severe COVID-19 patients (median illness duration: 36 days). Normal lung and idiopathic pulmonary fibrosis (IPF) were used for comparison. Twenty-seven patients with DAD and disease evolution of more than 2 weeks had fibrosis. Pathways and genes related with collagen biosynthesis and extracellular matrix (ECM) biosynthesis and degradation, myofibroblastic differentiation and epithelial to mesenchymal transition (EMT) were overexpressed in COVID-19. This pattern had similarities with that observed in IPF. By immunohistochemistry, pathological fibroblasts (pFBs), with CTHRC1 and SPARC expression, increased in areas of proliferative DAD and decreased in areas of mature fibrosis. Immunohistochemical analysis demonstrated constitutive expression of cadherin-11 in normal epithelial cells and a similar pattern of cadherin and catenin expression in epithelial cells from both normal and COVID-19 samples. Transcriptomic analysis revealed downregulation of the Hippo pathway, concordant with the observation of YAP overexpression in hyperplastic alveolar epithelial cells. Progression to fibrosis in severe COVID-19 is associated with overexpression of fibrogenic pathways and increased in CTHRC1- and SPARC-positive pFBs. Whereas the Hippo pathway seemed to be implicated in the response to epithelial cell damage, EMT was not a major process implicated in COVID-19 mediated lung fibrosis.
Keywords